itolizumab

mAbexperimental

Itolizumab is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana. — Wikipedia

Clinical trial activity

10 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
2
Phase 4
0

Earliest trial started Jun 20, 2019 (NCT04007198)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07105852Phase 2Jul 3, 2025Zhejiang University
NCT05978544Phase 1Dec 31, 2023Biotech Pharmaceutical Co., Ltd., Chinese Academy of Medical Sciences
NCT05986162Phase 1Dec 30, 2023Biotech Pharmaceutical Co., Ltd., Chinese Academy of Medical Sciences
NCT05823675Phase 1May 19, 2023Biotech Pharmaceutical Co., Ltd., Chinese Academy of Medical Sciences
NCT05263999Phase 3Apr 29, 2022Biocon Limited, Equillium
NCT04605926Phase 3Nov 30, 2020Biocon Limited, Equillium
NCT04475588Phase 2May 1, 2020Biocon Limited
NCT04128579Phase 1Oct 1, 2019Biocon Limited, Equillium, University of California, San Diego
NCT03763318Phase 1/Phase 2 (Phase 2)Jun 30, 2019Biocon Limited, Equillium
NCT04007198Phase 1Jun 20, 2019Biocon Limited, Equillium, Melbourne Health
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Biocon LimitedFor profit6132019
EquilliumFor profit5532019
Biotech Pharmaceutical Co., Ltd.For profit3312023
Chinese Academy of Medical SciencesAcademic/Hospital3012023
Melbourne HealthAcademic/Hospital1012019
University of California, San DiegoAcademic/Hospital1012019
Zhejiang UniversityAcademic/Hospital1112025
7 organizations
Page 1 / 1